                         SEQUENCE LISTING

<110>  New England Biolabs, Inc.
 
<120>  Target Enrichment

<130>  DG-003

<150>  62/781,762
<151>  2018-12-19

<160>  4     

<170>  PatentIn version 3.5

<210>  1
<211>  81
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic construct


<220>
<221>  misc_feature
<222>  (33)..(44)
<223>  n is a, c, g, or t

<400>  1
gatcggaaga gcgtcgtgta gggaaagagt gtnnnnnnnn nnnnaggcta tagtgtagat       60

ctcggtggtc gccgtatcat t                                                 81


<210>  2
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic construct

<400>  2
aatgatacgg cgaccacc                                                     18


<210>  3
<211>  82
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic construct


<220>
<221>  misc_feature
<222>  (38)..(49)
<223>  n is a, c, g, or t

<400>  3
aatgatacgg cgaccaccga gatctacacc gaatacgnnn nnnnnnnnna cactctttcc       60

ctacacgacg ctcttccgat ct                                                82


<210>  4
<211>  34
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic construct

<400>  4
agatcggaag agcacacgtc tgaactccag tcac                                   34


